



# ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: [www.americasblood.org](http://www.americasblood.org)

2019 #13

April 19, 2019

## INSIDE:

WORD IN WASHINGTON .....	2
ABC Seeks Committee Volunteers for FY 2020-21 .....	4
Out of Hospital Transfusion Survey Now Open .....	4
Registration Extended for ABC Technical and Quality Workshop .....	4
RESEARCH IN BRIEF .....	5
RECENT REVIEWS .....	5
BRIEFLY NOTED .....	6
REGULATORY NEWS .....	6
MEMBER NEWS .....	7
PEOPLE .....	7
GLOBAL NEWS .....	8
Upcoming ABC Webinars – Don't Miss Out! .....	8
STOPLIGHT®: Status of America's Blood Centers' Blood Supply .....	9
ABC 2019 Meetings & Workshops .....	9
COMPANY NEWS .....	10
CALENDAR .....	10
POSITIONS .....	11

## CBER 2018 Director's Report Available

The U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) published its fiscal year [2018 Report from the Director](#) this week. The report includes the agency's accomplishments from last year and several with relevance to the blood community.

"CBER/FDA [granted](#) an Emergency Use Authorization to the Department of Defense to enable the use of Freeze-Dried Plasma to treat hemorrhage or coagulopathy of U.S. military personnel injured during military combat when plasma is not available or its use is not practical", stated CBER in a message accompanying the report from director Peter Marks, MD, PhD.

He continued, "FDA's ongoing contributions to controlling Zika virus included CBER's approval of the [cobas](#) Zika Test and the Procleix Zika Virus Assay (Nucleic Acid Tests), the first donor screening tests for the direct detection of Zika Virus RNA in human plasma from individual donors. The report [highlights] these and other CBER accomplishments that reflect our responses to new and ongoing scientific and regulatory challenges, such as those posed by advanced therapies, emerging infectious diseases, and threats to the blood supply. It also reflects how we are carefully focusing our own research and stakeholder outreach so they support our efforts to meet those challenges."

The report lists additional noteworthy achievements in the Office of Blood Research and Review as the approval of the Imugen *Babesia microti* (*B. microti*) [Arrayed Fluorescent Immunoassay](#) (AFIA) and their [B. microti Nucleic Acid Test](#) (NAT) used extensively under investigational new drug applications (IND) for donor screening in high-risk regions of the Northeast U.S., and holding two FDA Blood Products Advisory Committee (BPAC) meetings to discuss reducing the risk of Zika transmission and strategies to reduce the risk of bacterial contamination of platelets. The complete report is available [here](#).

(Source: CBER 2018 [Report](#) from the Director, 4/17/19) ♦

## 22<sup>nd</sup> Annual Awards of Excellence Photos Available

Photos are available on ABC's [Flickr page](#) from the *Awards of Excellence* celebration, held in conjunction with the ABC Annual Meeting. Each year, ABC and its member blood centers recognize individuals and organizations that have made outstanding contributions in promoting blood donation and improving transfusion medicine. The complete set of photos from this year and previous years can be downloaded now.



## WORD IN WASHINGTON

The White House Office of Management and Budget (OMB) has distributed a [memo](#) that mandates federal agencies provide non-binding guidance to the Office of Information and Regulatory Affairs (OIRA) and potentially Congress as well. This could alter and slow the U.S. Food and Drug Administration’s (FDA) guidance process. The memo came from OMB Acting Director Russell Vought on April 11<sup>th</sup> and reemphasized the Congressional Review Act (CRA) which requires federal agencies to submit rules to OIRA to deem if they are major, a classification that would necessitate Congressional review. “Agencies should not publish a rule--major or not major--in the Federal Register, on their websites, or in any other public manner before OIRA has made the major determination and the agency has complied with the requirements of the CRA,” the OMB memo states and would begin on May 11<sup>th</sup>. According to *Inside Health Policy*, “[t]he memo reiterates CRA, which says that a rule is considered major if it has resulted in or is likely to result in: an annual effect on the economy of \$100 million or more; a major increase in costs or prices for consumers, industries, government agencies or geographic regions; or significant adverse effects on competition, employment, investment productivity, innovation or U.S. companies’ ability to compete with foreign enterprises.”

(Source: *Inside Health Policy*, [Regulatory experts: OMB memo could drastically slow FDA Guidances](#), 4/13/19, OMB [Memo](#), 4/11/19)

The Senate Appropriation Committee’s Subcommittee on Labor, Health and Human Services, Education, and Related Agencies held a [hearing](#) last week to discuss the fiscal year 2020 Budget Request for the National Institutes of Health (NIH). Francis Collins, MD, PhD, director of NIH, [testified](#) presenting the agencies priorities which include investments in HIV/AIDS research, cancer treatments, and precision medicine. “The All of Us Research Program is committed to engaging individuals from all walks of life, including those who may not have been asked to participate in research previously, and more than 75 percent of participants are from communities that have been underrepresented in biomedical research. This diversity has the power to revolutionize standards for inclusivity in research and for generalizability of biomedical research findings across many communities, with the ultimate goal of spurring discoveries that bring the promise of precision medicine to all of us,” said Dr. Francis’ prepared statement. The Administration’s proposed budget would cut NIH funding by more than \$4 billion. Senate Appropriation Committee Chair Sen. Richard Shelby (R-Ala.) stated that he is against such cuts emphasizing his support for the work of NIH according to *Politico*, “I’m not interested in cutting your budget, I’m interested in increasing it. We will have a big struggle this year dealing with the budget, but I think this is a great investment for America and for the world.”

(Source: Committee [Hearing](#), 4/11/19)

(continued on page 3)

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2019 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the healthcare system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

### America’s Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Louis Katz

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

**Annual Subscription Rate: \$390**

Send subscription queries to

[lmaundy@americasblood.org](mailto:lmaundy@americasblood.org)

America’s Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).



WORD IN WASHINGTON (continued from page 2)

Sen. Chuck Grassley (D-Iowa) Chair of the Senate Finance Committee sent a [letter](#) to U.S. Department of Health and Human Services (HHS) Secretary Alex Azar inquiring about the agency's response to cybersecurity vulnerabilities revealed in the Office of the Inspector General's (OIG) [Report](#). Several vulnerabilities were enumerated in the OIG report ranging from critical to low risk that could impact the integrity of HHS's network. Sen. Grassley specifically asked:

1. Which HHS departments were notified via early alerts about the HHS OIG's findings?
  - a. On what date(s) were the HHS departments notified of the early alerts?
  - b. What actions were taken to address the issues raised in the early alerts?
2. Has HHS implemented any new agency-wide cyber policies to address concerns raised in the HHS OIG report? If so, what are they and when were they implemented?
3. With respect to the HHS OIG recommendations, please provide the Committee a written summary, on a rolling basis if necessary, describing how HHS has implemented fixes sufficient to close the recommendations.
4. Please provide the Committee a timeline outlining the implementation of the recommended policies and anticipated dates of compliance.

Answers to the questions are expected next week with a full briefing provided by the end of the month.

(Source: Sen. Grassley News [Release](#) 4/9/19) 💧

AMERICA'S  
BLOOD  
CENTERS'

## TECHNICAL AND QUALITY WORKSHOP

Bloomington, MN | April 30 - May 2, 2019





**HOTEL INFORMATION:**  
Embassy Suites Bloomington:  
Hotel room rate: \$139

**2019 WORKSHOP SCHEDULE**

<b>BCA IRL Disease Symposium:</b>	April 30
<b>Technical:</b>	April 30-May 1
<b>Joint Technical &amp; Quality:</b>	May 1
<b>Quality:</b>	May 2

**2019 WORKSHOP FEES**  
(EARLY BIRD/REGULAR)

**TD or QA:** \$360/\$420  
**TD and QA:** \$435/\$495

\*Registration for Technical or Quality includes the Joint Session.

**For registration information, visit [http://bit.ly/abc\\_tq19](http://bit.ly/abc_tq19).**

“ ABC is proud to partner with BCA to offer this multi-day educational event for quality and technical blood bank professionals. We hope you will join us for this unique opportunity to learn, collaborate and network with your colleagues from across the industry. ”

*— Kate Fry, MBA, CEO, America's Blood Centers*



INNOVATIVE  
BLOOD  
RESOURCES



New York Blood Center Enterprises



America's Blood Centers®  
It's About Life.

Sponsorship opportunities available. Contact Leslie Maundy at [lmaundy@americasblood.org](mailto:lmaundy@americasblood.org) for details.



**America's Blood Centers®**  
It's About *Life.*

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.*

### ABC Seeks Committee Volunteers for FY 2020-21

America's Blood Centers (ABC) issued the call for ABC committee volunteers. These individuals play an integral role driving the work of the association and will serve a two-year term. ABC encourages participation from all interested individuals that work on the staffs of ABC's member blood centers. Additional details and the link to sign-up are available in [MCN 19-029](#). Please contact [Toni Mattoch](#) with questions. A full listing of committees and subcommittees are below:

- [Bylaws Committee](#)
- [Leadership and Meetings Committee](#)
- [Membership Committee](#)
- [Public Policy Council](#)
- [Quality Committee](#)
  - Quality Education Subcommittee
  - Regulatory Review Subcommittee – Blood
  - Regulatory Review Subcommittee - HCT/P
- [Scientific, Medical, Technical Committee](#)
  - SMT Journal Club
  - SMT Publications Subcommittee (Blood Bulletin)

(Source: MCN [19-029](#))

### Out of Hospital Transfusion Survey Now Open

ABC is seeking input from member blood centers in the Out of Hospital Transfusion Survey. With the number of transfusions outside of the traditional hospital setting continuing to increase, this survey will assess the out of hospital transfusions in the service areas of ABC members. All ABC member blood centers are encouraged to complete the survey. The results will be shared with the ABC membership and featured during a session at the upcoming ABC Technical and Quality Workshop. More information including the survey link can be found in [MCN 19-028](#).

(Source: MCN [19-028](#))

### Registration Extended for ABC Technical and Quality Workshop

[Register](#) today for the ABC Technical and Quality Workshop in Bloomington, Minn. at the Embassy Suites Bloomington. This year, ABC and Blood Centers of America, Inc. (BCA) are partnering to provide a multi-day professional development and educational opportunity for quality and technical blood bank professionals. The BCA IRL Networking Conference/IRL Disease Symposium will take place on April 29-30<sup>th</sup> with the ABC Quality (QA) & Technical Directors (TD) Workshops following it on April 30<sup>th</sup>- May 2<sup>nd</sup>. Additional schedule and registration information are below:

(continued on page 5)

INSIDE ABC (continued from page 4)

- April 29: BCA IRL Networking Conference (*BCA members-only; BCA will provide registration information*)
- April 30: BCA IRL Disease Symposium (*All ABC members welcome; no registration fee; ABC will provide symposium registration*)
- April 30 – May 1: TD Workshop and Joint TD/QA Session
- May 2: QA Workshop

## Registration &amp; Fees:

- Breakfast, lunch, and two receptions included.
- ABC QA/TD Workshop Registration Fees:
  - TD or QA Workshop: \$420 regular
  - TD & QA Workshop: \$495 regular ♦

**We Welcome Your Letters**

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at [newsletter@americasblood.org](mailto:newsletter@americasblood.org) or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.

**RESEARCH IN BRIEF**

**A supplement to *Transfusion* reviews the current status of blood product options for trauma in 22 papers which are available [open access](#).** An introduction concludes “the changes back to a blood-based resuscitation for bleeding and avoidance of crystalloids has led to the battle cry of the Trauma, Hemostasis, and Oxygenation Research (THOR) Network, BLOOD IS FOR BLEEDING, SALT WATER IS FOR COOKING PASTA.” The invited manuscripts and original research cover the epidemiology and treatment of military and civilian injuries, the optimal products for resuscitation, novel products in development and evaluation, compatibility testing including measurement of isohemagglutins, transport of blood using drones, and the evaluation of coagulopathy among other topics.

**Citation:** Special Issue: [A Supplement to \*Transfusion\*, The THOR Network 2018 Remote Damage Control Resuscitation Symposium](#). *Transfusion*. 2019. ♦

**RECENT REVIEWS**

**A brave new world coming to a transfusion service near you?** An article in the *New England Journal of Medicine* reviews the current status of development and potential applications of machine learning to medical practice asking the question “what if every medical decision, whether made by an intensivist or a community health worker, was instantly reviewed by a team of relevant experts who provided guidance if the decision seemed amiss?” The authors then note of such a system, “[t]here are not enough medical experts to staff it, it would take too long for experts to read through a patient’s history, and concerns related to privacy laws would stop efforts before they started;” but this is the promise of machine learning, the

(continued on page 6)



INSIDE ABC (continued from page 5)

mining of the expertise developed by many clinicians based on the outcomes of huge patient populations — the real time integration of the lessons from billions of encounters. Machine learning is then “explained” in accessible language, and how it might be applied to support diagnostic, prognostic, therapeutic decision making, and the operational efficiency of care delivery. The key challenges discussed include the availability of data of adequate quality, limited generalizability to particular clinical scenarios, and the risk that its availability will promote decreased provider vigilance for errors (automation bias). The “cautiously optimistic” authors “look forward to the hopefully not-too-distant future when all medically relevant data used by millions of clinicians to make decisions in caring for billions of patients are analyzed by machine-learning models to assist with the delivery of the best possible care to all patients.”

**Citation:** Rajkomar, A., Dean, J., Kohane, I. Machine learning in medicine. *N. Engl. J. Med.* 2019. doi: [10.1056/NEJMra1814259](https://doi.org/10.1056/NEJMra1814259). ♦

**BRIEFLY NOTED**

**A podcast exploring the rise and fall of Ambrosia, one of the companies at the center of the controversy surrounding the purported health and aging benefits of plasma infusions, has been [released](#).** *Decrypted* examines “Young Blood and the Pursuit of Eternal Youth” and includes a patient interview with opinions from researchers and scientists. The U.S. Food and Drug Administration (FDA) [warned](#) the public about the claims of establishments that offer plasma infusions from young human donors to treat aging and ailments such as dementia and Parkinson’s disease earlier this year. Several establishments had opened around the U.S. marketing the supposed benefits of young plasma infusions, which concerned the FDA. In a February 19<sup>th</sup> joint [statement](#) released from former FDA Commissioner Scott Gottlieb, MD and director of FDA’s Center for Biologics Evaluation and Research (CBER) Peter Marks, MD, PhD, the FDA stated “[t]here is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat, or prevent these conditions, and there are risks associated with the use of any plasma product...Our concerns regarding treatments using plasma from young donors are heightened by the fact that there is no compelling clinical evidence on its efficacy, nor is there information on appropriate dosing for treatment of the conditions for which these products are being advertised. Plasma is not FDA-recognized or approved to treat conditions such as normal aging or memory loss, or other diseases like Alzheimer’s or Parkinson’s disease. Moreover, reports we’re seeing indicate that the dosing of these infusions can involve administration of large volumes of plasma that can be associated with significant risks including infectious, allergic, respiratory, and cardiovascular risks, among others.”

(Source: *Bloomberg*, [Young blood and the pursuit of eternal youth](#), 4/9/19) ♦

**REGULATORY NEWS**

**The U.S. Food and Drug Administration (FDA) published a summary of important information for blood establishments and transfusion services [entitled](#) “*Acinetobacter sp.* Contamination of Platelets for Transfusion.”** The agency reports that four platelet components from apheresis platelet collections spanning the U.S. resulted in septic transfusion reactions, including one fatality. Two of the components were not transfused. These reactions were not detected by various bacterial mitigation measures. Contamination in the fourth collection was identified by bacterial testing and discarded. FDA and The Centers for Disease Control and Prevention (CDC) are investigating these reports and additional information will be forthcoming. The FDA is encouraging blood establishments and transfusion services to contact them concerning any cases of *Acinetobacter sp.* contamination of platelets. ABC encourages member blood centers to review their procedures including environmental cleaning. We will provide additional information as it becomes available.

(Source: FDA [Announcement](#), 4/16/19) ♦



## MEMBER NEWS

**Versiti Blood Research Institute** has received a seven-year contract from the U.S. Department of Health and Human Services (HHS) to continue its participation in the Recipient Epidemiology and Donor Evaluation Study (REDS) now in the 4<sup>th</sup> phase. “As blood health innovators, Versiti is honored to continue our participation in this program to advance the safety, collection and usage of blood products,” said Versiti Blood Research Institute Medical Director and Senior Investigator Alan Mast, MD, PhD, in a [news release](#). “Blood transfusions are the most common procedure in healthcare, but the least understood. By tracking transfusions from vein-to-vein, we will learn how specific factors in blood donors can affect and improve patient outcomes.” REDS-IV will examine the safety and efficacy of blood transfusions and patient outcomes in adults and children. “Scientific research is the foundation for tomorrow’s discoveries. Over the years, Dr. Mast and his team have dedicated themselves and made significant contributions to what the REDS program has built. Our future research will help make the next breakthrough in transfusion medicine possible, ensuring better care and outcomes for patients with transfusion needs,” added Versiti Executive Vice President of Research and Chief Scientific Officer Gilbert White, MD. Versiti Blood Research began participating in REDS in 2004 and will partner with Froedtert & the Medical College of Wisconsin, Children’s Hospital of Wisconsin, and Marshfield Clinic during the current phase of the program.

(Source: Versiti News [Release](#), 4/18/19)



**Community Blood Center of the Carolinas (CBCC)** and **OneBlood** have finalized their merger as of April 15<sup>th</sup>. The merger culminates four months of collaborative work to transition CBCC into the OneBlood brand as integration efforts continue for technological and operational platforms. “CBCC’s decision to join forces with OneBlood creates additional alignment and stability of the blood supply in the

Southeastern United States and further ensures a safe, available, and affordable blood supply for our hospital partners and their patients,” said Bud Scholl, president and CEO of OneBlood in a [news release](#). As a part of the merger, CBCC CEO Martin Grable will become a member of the OneBlood leadership team as the executive vice president of Corporate Development, “I am excited to take on this new role and further expand our lifesaving services in the Carolinas and throughout the Southeastern United States.” OneBlood will now distribute more than 1 million blood products annually while serving more than 250 hospitals in Florida, North Carolina, South Carolina, Georgia, and Alabama.

(Source: OneBlood News [Release](#), 4/15/19) 💧

## PEOPLE



**Jennifer Hutchinson** has joined Versiti Blood Center of Ohio as senior account representative. She becomes the first employee of Versiti’s expansion into Ohio. Ms. Hutchinson has a strong working knowledge of community engagement with schools, churches, and other community organizations, including six years of experience organizing 360 community blood drives annually for the American Red Cross. “Jennifer’s passion for our mission, her extensive experience in blood collections and her strong connections throughout Ohio will truly make a difference and help save countless lives,” said Versiti CEO Chris Miskel, MBA. “Jennifer’s strength in building community relationships and engaging blood donors will be critical to our commitment to serve Ohio.” Ms. Hutchinson will serve as the primary contact for organizations and individuals wishing to schedule blood drives in the Columbus-area,

(continued on page 8)

PEOPLE (continued from page 7)

“[a]s a blood services representative and community partner, I’m able to help people realize their dreams of truly making a difference in patient lives. People in our community become heroes when they decide to become a blood donor or a volunteer blood drive coordinator and it is truly an honor to serve these individuals. I’m particularly excited to help ensure a plentiful blood supply for The Ohio State University Wexner Medical Center. I look forward to building relationships and helping members of the community become the beacons of hope through blood donation,” added Ms. Hutchinson.

(Source: Versiti Announcement, 4/18/19) ◆

**GLOBAL NEWS**

**Regulators in the United Kingdom (UK) are working to meet increasing demand for immunoglobulin (IVIg) amid mounting pressure from patient advocacy groups to remove a ban on the production of IVIg.** The UK ban dates back to concerns over variant Creutzfeldt-Jakob Disease (vCJD) in the 1990s. A [report](#) in *BBC Wales* chronicles the battle of an 8-year-old patient undergoing treatment for primary immune deficiency which requires regular infusions of IVIg. It highlights that patients’ treatment options may be limited from the IVIg supply shortage that the UK has been experiencing, “[i]n the past, immunologists would try and assess which product would be better for each patient,” said patient advocate Liz Macartney in the article. “At the moment, we just have to accept whatever the NHS can buy. Potentially it could be devastating.” Demand has risen by 35 percent in Wales since 2013 according to the article as UK officials continue to work with NHS England and suppliers to meet the growing need for IVIg. Suppliers are aiming to become more efficient to maximize the effectiveness of their product, “[m]anufacturers...are also looking at ways to innovate new technologies so they can get more grams of immunoglobulin per every unit of plasma,” said Chloe George of the Welsh Blood Service to *BBC Wales*.

(Source: *BBC Wales*, [Call to end ban on producing immune therapy from UK blood](#), 4/15/19)

**Upcoming ABC Webinars – Don’t Miss Out!**

- **QA Education Webinar – Change Management** – July 16th. Additional details forthcoming!

**ABC Calendar of Events**

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!







## STOPLIGHT®: Status of America's Blood Centers' Blood Supply

Total ABC Red Cell Inventory

Percent of Regional Inventory at 2 Days Supply or Less, April 17, 2019



Percent of Total ABC Blood Supply Contributed by Each Region  
 East: 20%; Midwest: 25%; South: 24%; West: 31%

Daily updates are available at:  
[www.AmericasBlood.org](http://www.AmericasBlood.org)

ABC 2019 Meetings & Workshops				
Meeting/Workshop	Dates	Location	Hotel/Hotel Rate	Registration Dates & Fees
Technical & Quality Workshop	April 30-May 2	Bloomington, Minnesota	Embassy Suites, \$139/night	<a href="#">Register here</a> (TD or QA or TD + QA) \$420/\$495
<a href="#">ADRP Annual Conference</a>	May 14-16	Indianapolis, Indiana	Hyatt Regency, \$179/night	<a href="#">Register here now</a> Subscribers \$575/\$695 non-subscribers
Medical Directors Workshop	July 30 (precedes Summer Mtg)	Denver, Colorado	Grand Hyatt, \$239/night	Late April - July 5 MD Workshop \$435 MD+Summer \$760
Summer Meeting	July 31-August 1	Denver, Colorado	Grand Hyatt, \$239/night	Late April - July 5 Summer \$655 Summer+MD \$760
<p><b>Notes:</b>                      For the most up-to-date information on all events, members of ABC may check the <a href="#">calendar</a> on ABC's Member Site.                      Non-members may attend all events; information will be updated on ABC's <a href="#">Public Site</a>.</p>				



## COMPANY NEWS

**CRISPR Therapeutics** and **Vertex Pharmaceuticals** have [received](#) fast track designation from the U.S. Food and Drug Administration for its investigational, autologous, gene-edited hematopoietic stem cell therapy (CTX001) for the treatment of transfusion-dependent beta thalassemia. Previously, the companies received fast track designation for CTX001 in the treatment of sickle cell disease with phase 1 and 2 clinical trials underway for beta thalassemia and sickle cell disease patients respectively.

(Source: CRISPR Therapeutics & Vertex Pharmaceuticals Joint News [Release](#), 4/16/19) ♦



## CALENDAR

***Note to subscribers:** Submissions for a free listing in this calendar are welcome. Send information to Leslie Maundy by e-mail ([lmaundy@americasblood.org](mailto:lmaundy@americasblood.org)) or by fax to (202) 899-2621. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

### 2019

April 23-24. **15<sup>th</sup> Annual FDA and the Changing Paradigm for HCT/P Regulation, Washington, D.C.** More details available [here](#).

April 30-May 2. **2019 ABC Technical & Quality Workshop, Minneapolis, Minn.** More details available [here](#).

May 14-16. **ADRP Annual Conference, Indianapolis, Ind.** More details available [here](#).

May 22-23. **IPFA/PEI 26th International Workshop on "Surveillance and Screening of Blood-Borne Pathogens", Krakow, Poland.** More details available [here](#).

July 30-Aug. 1. **2019 ABC Medical Directors Workshop & Summer Meeting, Denver, Colo.** More details coming soon.



## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, contact Leslie Maundy at the ABC office. Phone: (202) 654-2917; fax: (202) 899-2621; e-mail: [lmaundy@americasblood.org](mailto:lmaundy@americasblood.org).

## POSITIONS

**Component Lab Director.** Innovative Blood Resources is seeking a Component Lab Director located in our St. Paul headquarters. Responsibilities: Provide supervision, development, support, and mentoring to our three Component Labs located in St. Paul, Duluth and Lincoln. Facilitate standardization between labs and divisions. Ensure a culture of continuous process improvement. Qualifications: Bachelor's degree: in Biology Sciences, Medical Technology, or Clinical Laboratory Science. Five years laboratory experience. Five years leadership or supervisory experience. Apply today! View full job descriptions on [www.innovativebloodresources.org/careers/](http://www.innovativebloodresources.org/careers/). Applicants must apply and submit a resume online to be considered.

**Manager, Donor Center Operations.** LifeStream (San Bernardino, CA) located 60 miles east of Los Angeles and 50 miles west of Palm Springs seeks qualified applicants for its Manager, Donor Center Operations. This position reports to the Director, Donor Operations and oversees seven donor centers in the region. Responsibilities include ensuring strong customer service, efficient operations and compliance to cGMP Standards. Duties also include oversight of staff training, assignments and performance, equipment monitoring and Quality Control. Responsibilities also include monitoring and trending of donor center productivity and facility/equipment management. Bachelor's degree in Business Administration, Human Resources, Nursing or Medical Technology with relevant supervisory/management experience; or three to five years supervisory experience in a Blood Bank setting. Management experience highly preferred. Three to four years of supervisory experience required with a high level of problem-solving and organizational skills; computer literate; excellent written and oral communication skills; able to maintain confidential information; demonstrate ability to learn and apply new skills efficiently. Current CPR certification and current California driver's license required. Excellent benefits package with relocation reimbursement available for qualified candidates. LifeStream is an Equal Opportunity Employer, M/F/D/V. LifeStream participates in the Federal government E-verify program to determine employment eligibility. **Apply online at** <https://www.lstream.org/open-positions/>

**Senior Director, Member Programs and Services.** America's Blood Centers (ABC), North America's largest network of community-based, independent blood programs, is seeking a Senior Director, Member Programs and Services. The position is a key senior management role and will lead a team tasked with the development and execution of innovative solutions that maximize ABC member engagement and promote ABC products, programs and services. The position will report directly to the Chief Executive Officer, providing strategic guidance on emerging trends in association management and the blood banking industry to help shape strategies that increase growth and drive revenue. Primary Responsibilities: Implement a long-term strategy

to position the association's programs and services with a focus on member engagement and revenue growth. Provide leadership and support for the design, development and implementation of ABC meetings and workshops, including budgeting, content, logistics, sponsorships, and marketing. Seek and assess feedback and market analysis to implement, revise, and strengthen ABC's membership offerings. Identify opportunities related to member retention and growth. Oversee ABC publications and member and public websites to maximize value to ABC members and promote additional revenue streams where possible. Educational requirements: Bachelor's required. Click [here](#) to view the full job description. Interested applicants should send a cover letter and resume to [careers@americasblood.org](mailto:careers@americasblood.org).

**Manager, Grassroots and Communications.** America's Blood Centers (ABC), North America's largest network of community-based, independent blood programs, is seeking a Manager, Grassroots and Communications for our expanding advocacy team. The position will assist in managing issue advocacy campaigns, implementing new grassroots programs and developing a robust network of blood advocates. This position will also oversee ABC public relations and communications efforts, including developing and executing robust communication and marketing plans to promote ABC, its member blood centers, and the importance of blood donation. Primary responsibilities: Manage and expand ABC's member grassroots advocacy programs and campaigns, including site visits, our annual Day on Capitol Hill, education and training throughout the year, and material development. Develop and promote activities that recruit grassroots volunteers and build a grassroots network that includes blood donors, patients, community partners, and other stakeholders. Execute and deliver industry and association messaging and communications to critical audiences around Association's priorities and ensure digital, social and earned media efforts and goals are fully integrated and aligned with ABC's Advocacy Agenda. Educational requirements: Bachelor's required. Click [here](#) to view the full job description. Interested applicants should send a cover letter and resume to [careers@americasblood.org](mailto:careers@americasblood.org).

**Senior Director, Federal Government Affairs.** America's Blood Centers (ABC), North America's largest network of community-based, independent blood programs, is seeking a Senior Director, Federal Government Affairs. The position is a key senior management role and will lead the day-to-day activities of an expanding advocacy team. The position will be actively involved and accountable for the development, prioritization, tracking, communication, and accomplishment of public policies impacting ABC members at the federal level. The position will report directly to the Chief Executive Officer, providing strategic guidance on government affairs and

(continued of page 12)

POSITIONS (continued from page 11)

public policy issues pertaining to the nation's blood supply. Primary Responsibilities: Represent ABC before the U.S Congress and key federal agencies, building and maintaining strong relationships and improving the visibility of ABC member centers. Work closely with the CEO, Chief Medical Officer, and Government Relations team to define ABC's public policy and advocacy focus and develop positions and strategies on legislative, policy, and regulatory priorities. Oversee the development of a comprehensive and coordinated strategy to leverage direct lobbying, grassroots advocacy, and coalition building in the advancement of ABC's Advocacy Agenda. Educational requirements: Bachelor's required. Click [here](#) to view the full job description. Interested applicants should send a cover letter and resume to [careers@americasblood.org](mailto:careers@americasblood.org).

**Medical Director.** Provide transfusion medicine (TM) clinical care at Heartland Blood Center (HBC) and its associated hospitals in the scope noted below, as well as effort in leadership of the Immunohematology Reference Laboratory (IRL) as Medical Director at HBC/Versiti. Key components of this position would comprise TM consultation and oversight of blood management at HBC and Versiti partner hospitals, as well as participation in educational initiatives and clinical/applied research within both Versiti blood centers and their affiliated health systems. Primary Responsibilities: Oversees blood donor center collections in the Chicago-land and various areas of Indiana. Provides medical direction, including compliance with local, state, and federal regulations and accreditation agencies, for blood center and transfusion services at Versiti affiliated hospitals in Illinois and Indiana. IRL Medical Director for HBC, providing oversight of IRL laboratory staff technical duties and working with Versiti and HBC laboratory management to provide education and skill advancement. Education and Licenses: M.D. or D.O. Degree. Board certified in pathology (AP/CP or CP only), internal medicine, or pediatrics (with subspecialty boards in hematology). Board certified/board eligible in Blood Banking/Transfusion Medicine (American Board of Pathology—ABP). Current or eligible for medical licenses in Illinois, Wisconsin, Indiana, Michigan and Ohio. Experience/Certifications: Demonstrated experience in both 1) pathology/laboratory medicine or hematology and 2) transfusion medicine. Ability to write lectures and articles using original or innovative techniques or styles; excellent presentation skills with capacity to present to varied audiences. Click [here](#) to view the full job description and to apply. 💧